Earnings Feed
Start Free
Calumet, Inc. /DE·4

Feb 26, 8:51 PM ET

Sajkowski Daniel J 4

Research Summary

AI-generated summary

Updated

Calumet (CLMT) Director Daniel J. Sajkowski Sells Shares

What Happened Daniel J. Sajkowski, a director of Calumet, Inc. (CLMT), sold a total of 82,000 shares in five open‑market disposals between March and July 2025. The transactions were for: 20,000 shares on 2025-03-03 at a weighted avg $13.73 ($274,600); 20,000 on 2025-04-01 at $12.55 ($251,000); 20,000 on 2025-05-01 at $10.66 ($213,200); 20,000 on 2025-06-02 at $13.40 ($268,000); and 2,000 on 2025-07-01 at $15.77 ($31,540). Total proceeds across these sales were roughly $1.038 million. These were sales (not purchases) and were effected pursuant to a pre-established trading plan.

Key Details

  • Transaction dates & amounts:
    • 2025-03-03: 20,000 shares @ weighted avg $13.73 — $274,600 (F2: price range $13.35–$14.06)
    • 2025-04-01: 20,000 shares @ weighted avg $12.55 — $251,000 (F3: $12.06–$12.91)
    • 2025-05-01: 20,000 shares @ weighted avg $10.66 — $213,200 (F4: $10.40–$10.90)
    • 2025-06-02: 20,000 shares @ weighted avg $13.40 — $268,000 (F5: $13.07–$13.86)
    • 2025-07-01: 2,000 shares @ weighted avg $15.77 — $31,540 (F6: $15.53–$16.02)
  • Shares owned after the transactions: Not specified in the material provided in this summary (see the Form 4 for reported holdings).
  • Notable footnotes:
    • Sales were effected under a Rule 10b5-1 trading plan adopted March 14, 2024 (F1).
    • Several reported prices are weighted averages; the filing discloses price ranges and offers to provide per‑trade breakdown on request (F2–F6).
    • The filing notes Calumet became successor issuer to Calumet Specialty Products Partners on July 10, 2024 (unit-to-share conversion).
  • Filing timeliness: The Form 4 was filed on 2026-02-26 for transactions in 2025 (period of report 2025-03-03), which is later than the typical two-business-day SEC reporting window for insider trades.

Context

  • Because these sales were made under a pre-established Rule 10b5-1 plan, they are scheduled transactions and are generally considered routine rather than a direct, contemporaneous signal of the insider’s view of the company. For retail investors, scheduled sales reduce the informational value compared with discretionary, same‑day insider sales.